Investor Relations > 2013 Press Releases

2013 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
12/26/13Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Dec. 26, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today announced that the Texas Attorney General has agreed to close its investigation of Hi-Tech's pricing of products that were purchased with Texas Medicaid dollars. In settlement, Hi-Tech agreed to pay $25,000,000 to the State of Texas. This amount had previously been accrued in the Company's financial statements. The settlement does not constitute an admission, finding or evidence of any liability or... 
Printer Friendly Version
12/10/13Hi-Tech Pharmacal Reports Sales of $58.6 million for the Second Quarter Ended October 31, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Dec. 10, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the second fiscal quarter ended October 31, 2013. Net sales of $58.6 million for the second quarter compared to $57.5 million for the same prior year period GAAP income of $1.2 million or $0.08 per diluted share for the second quarter Adjusted non-GAAP net income of $10.0 million or $0.71 per diluted share for the second quarter Net sales of $109.1 million for the s... 
Printer Friendly Version
09/09/13Hi-Tech Pharmacal Reports Sales of $50.5 Million for the First Quarter Ended July 31, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Sep. 9, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the Company's fiscal first quarter ended July 31, 2013. Net sales of $50.5 million for the first quarter compared to $52.0 million for the same prior year period GAAP income of $4.6 million or $0.33 per diluted share for the first quarter Adjusted non-GAAP net income of $6.1 million or $0.44 per diluted share for the first quarter       ... 
Printer Friendly Version
09/05/13Hi-Tech Pharmacal to Release First Quarter Earnings and Hold Conference Call on September 9, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Sep. 5, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) announced that the Company will release results for its first quarter of Fiscal Year 2014 ended July 31, 2013, prior to the market opening on Monday September 9, 2013 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time. To access the conference call, dial toll free 877-415-3182, or 857-244-7325 for international callers, five minutes before the conference. The passco... 
Printer Friendly Version
08/27/13Akorn to Acquire Hi-Tech Pharmacal for $640 Million
- Over $500 million in combined revenues – - Immediately accretive to non-GAAP earnings, before synergies – - $15-20 million in annual run-rate synergies expected within 12 months post-close – - Strong combined cash flow allows for rapid pay-down of debt - LAKE FOREST, IL— August 27, 2013 -- Akorn, Inc. (NASDAQ: AKRX) and Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that they have entered into a definitive agreement under which Akorn will acquire Hi-Tech for... 
Printer Friendly Version
07/24/13Health Care Products Division of Hi-Tech Pharmacal Receives FDA Warning Letter Related to Labeling Statements on Certain OTC Products
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jul. 24, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that its Health Care Products Over The Counter (OTC) division received a Warning Letter from Food and Drug Administration (FDA) dated July 15, 2013. The Warning Letter is related to certain statements that appear on labeling of Diabeti-Derm® Antifungal Cream, Zostrix® Diabetic Foot Pain Relief Cream and Zostrix® Diabetic Joint & Arthritis Pain Relief Cream. HCP intends to fully comply wi... 
Printer Friendly Version
07/09/13Hi-Tech Pharmacal Reports Sales of $58.5 million for the Fourth Quarter Ended April 30, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jul. 9, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the fourth quarter and year ended April 30, 2013. Net sales of $58.5 million for the fourth quarter compared to $61.3 million for the same prior year period GAAP loss of $4.6 million or $0.34 per diluted share for the fourth quarter Adjusted non-GAAP net income of $6.9 million or $0.50 per diluted share for the fourth quarter Net sales of $232.4 million for the fiscal... 
Printer Friendly Version
07/03/13Hi-Tech Pharmacal to Release Fourth Quarter Earnings and Hold Conference Call on July 9, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Jul. 3, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its fourth quarter of Fiscal Year 2013 ended April 30, 2013, prior to the market opening on Tuesday July 9, 2013 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time. To access the conference call, dial toll free 877-280-4953, or 857-244-7310 for international c... 
Printer Friendly Version
05/09/13Hi-Tech Pharmacal to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
AMITYVILLE, N.Y.--(BUSINESS WIRE)--May. 9, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2013, at 10:00 a.m. Pacific Time. A live audio webcast of the Company's presentation can be accessed on the Investor Relations page of the Company's website: http://www.hitechpharm.com The webcast will be archived within one hour after the live event ... 
Printer Friendly Version
04/30/13ECR Pharmaceuticals Announces Re-launch of Zolpimist® and DexPak®, Divestiture of Hylase® and Orbivan® Brands, and Dr. Cameron Durrant Named President and CEO
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Apr. 30, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that its ECR Pharmaceuticals division re-launched Zolpimist® Oral Spray (zolpidem tartrate) and DexPak® Taperpaks (dexamethasone tablets) through its proprietary sales force at a series of launch meetings commencing this week. Additionally, ECR has divested its interest in non-core products Hylase® and Orbivan®. Hylase was divested for a one-time payment in January, and Orbivan® was di... 
Printer Friendly Version
04/29/13Hi-Tech Pharmacal to Present at the Needham 12th Annual Healthcare Conference
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Apr. 29, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the Needham 12th Annual Healthcare Conference Tuesday, April 29, 2013, at 10:40 a.m. Eastern Time. A live audio webcast of the Company's presentation can be accessed on the Investor Relations page of the Company's website: http://www.hitechpharm.com The webcast will be archived within one hour after the live event and will be... 
Printer Friendly Version
03/07/13Hi-Tech Pharmacal Reports Sales of $64.3 Million and EPS of $0.43 for the Third Quarter Ended January 31, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 7, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the Company's fiscal third quarter ended January 31, 2013. Quarterly Results Net sales for the three months ended January 31, 2013 were $64,331,000, an increase of $8,706,000 or 16% compared to the net sales of $55,625,000, for the three months ended January 31, 2012. Net sales for generic pharmaceuticals for the three months ended January 31, 2013 were $54,148,000, an in... 
Printer Friendly Version
03/04/13Hi-Tech Pharmacal to Release Third Quarter Earnings and Hold Conference Call on March 7, 2013
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 4, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced that the Company will release results for its third quarter of Fiscal Year 2013 ended January 31, 2013, prior to the market opening on Thursday March 7, 2013 and will hold a conference call to discuss its financial results at 10 a.m. Eastern Time. To access the conference call, dial toll free 800-798-2864, or 617-614-6206 for international callers, five minutes before the conference. The pass... 
Printer Friendly Version
02/26/13Hi-Tech Pharmacal to Present at the 2013 RBC Capital Markets’ Healthcare Conference
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Feb. 26, 2013-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today announced that it is scheduled to make an investor presentation at the 2013 RBC Capital Markets' Healthcare Conference Wednesday, February 27, 2013, at 11:00 a.m. Eastern Standard Time. A live audio webcast of the Company's presentation can be accessed on the Investor Relations page of the Company's website: http://www.hitechpharm.com The webcast will be archived within one hour after the li... 
Printer Friendly Version
HITK (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$43.49
Change (%) Stock is Down 0.01 (0.02%)
Volume150,000
Data as of 04/16/14 4:00 p.m. ET
Refresh quote
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Contact Information
Primary IR Contact
Anne Siebert
Phone: 631-789-8228
Ext. Ext. 4120
© Hi-Tech Pharmacal Co. Inc (a NASDAQ company)